Brofaromine - A review of its pharmacological properties and therapeutic use

Journal of Neural Transmission

Volumn 103, Issue 1-2, 1996, Pages 217-245

  Volz, H P ^a   Gleiter, C H ^a   Waldmeier, P C ^a   Struck, M ^a   Moller H J ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Brofaromine; Clinical trials; Pharmacology; Reversible and selective inhibitors of monoamine oxidase (type a)

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; BENSERAZIDE; BROFAROMINE; CLORGYLINE; GLIBENCLAMIDE; IMIPRAMINE; IPRONIAZID; ISOCARBOXAZID; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NIALAMIDE; PHENELZINE; SELEGILINE; SEROTONIN; TRANYLCYPROMINE;

BIOCHEMISTRY; BULIMIA; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG MECHANISM; FATIGUE; FLATULENCE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPERHIDROSIS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NARCOLEPSY; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PANIC; PHARMACOLOGY; PHOBIA; PRIORITY JOURNAL; REVIEW; SEROTONIN UPTAKE; SLEEP DISORDER; TACHYCARDIA; TREMOR; VERTIGO; XEROSTOMIA;

ANIMALS; BRAIN CHEMISTRY; DEPRESSIVE DISORDER; HUMANS; MONOAMINE OXIDASE INHIBITORS; PIPERIDINES;

EID: 0030025499     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01292628     Document Type: Article

References (99)

1. Andersen MC, Waldmeier PC, Tipton KF (1991) The inhibition of monoamine oxidase by brofaromine. Biochem Pharmacol 41: 1871-1877
2. Antonin KH, Jedrychowski M, Bieck PR (1990) Brofaromine. Pharmacodynamic and pharmacokinetic investigations in healthy subjects with a new reversible, selective MAO-A inhibitor. Miin Med Wochenschr 132 [Suppl 1]: 1, 13-17
3. Antonin KH, Kucher K, Fuchs L, Bieck PR, Schmidt E (1992) Investigation of dose proportionality and absolute bioavailability of brofaromine in healthy volunteers. Clin Neuropharmacol 15 [Suppl 1]: Pt B, 430B (Abstract)
4. Antonin KH, Fischer P, Nilsson E, Bieck PR (1994) Administration of L-DOPA and benserazide with the selective MAO-A inhibitor brofaromine in healthy volunteers: effect on blood pressure and DOPA metabolism. CINP, 120S
5. Antonin KH, Bieck PR (1994) Coadministration of brofaromine does not enhance insulin secretion and the hypoglycémie effect caused by glibenclamide. CINP, 120S
6. Baker GB, Coutts RT, Young JM, Hampston DR, Mclntosh GIJ, et al (1985)" Chronic administration of monoamine oxidase inhibitors: basic and clinical investigations. In: Boulton AA, et al (eds) Neuropharmacology of the trace amines. Humana Press, Clifton NJ, pp 317-328
7. Bianchi M, Mantegazza P, Panerai AE (1992) Effects of two different reversible monoamine oxidase-A inhibitors on nociceptive thresholds in the rat. Eur J Pharmacol 219: 113-116
8. Bieck PR, Nilsson E, Schick C, Waldmeier PC, Lauber J (1984a) Urinary excretion of tryptamine in comparison to normetanephrine and beta-phenylethylamine in human volunteers after subchronic treatment with different monoamine oxidase inhibitors. In: Boulton AA, Baker GB, Dewhurst WG, Sandler M (eds) Neurobiology of the trace amines. Humana Press, Clifton NJ, pp 525-539
9. Bieck PR, Antonin KH, Cremer G, Gleiter C (1984b) Tyramine presser effects of CGP 11 305A in comparison to tranylcypromine after prolonged treatment of human volunteers. In: Tipton KF, Dosiert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Academic Press, London, pp 505-513
10. Bieck PR, Kemmler H, Antonin KH, Tipton K (1988) Evidence of "local" gastrointestinal effects of MAO inhibition on metabolism and transport of tyramine in human subjects. Pharmacol Res Commun 20 [Suppl]: 129-130 (Abstract)
11. Bieck PR, Antonin KH (1988) Oral tyramine presser test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 8: 237-245
12. Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs. irreversible inhibitors. J Neural Transm 28 [Suppl]: 21-31
13. Bieck PR, Firkusny L, Schick C, Antonin KH, Nilsson E, Schulz R, Schwenk M, Wollmann H (1989) Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther 45: 260-269
14. Bieck PR, Antonin KH, Schulz R (1993) Clinical pharmacology of MAO-inhibitors. In: Yasuha H, Parvez SH, Oguchi K, Sandler M, Nagatsu S (eds) Monoamine oxidase: basid and clinical aspects. VSP, Utrecht, pp 177-196
15. British Medical Research Council (1965) Clinical trial of the treatment of depressive disorders. Br Med J 1: 881-886
16. Celada P, Pérez J, Alvarez E, Artigas F (1992) Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement. J Clin Psychopharmacol 12: 309-315
17. Chouinard G, Saxena BM, Nair NPV, Kutcher SP, Bakish D, Bradvwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA, Belanger ML, Snaith J, Beauclair L, Pohlmann H, D'Souza J (1994) A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord 32: 105-114
18. Da Prada M, Kettler R, Burkard WP, Haefely WE (1984) Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In: Tipton KF, Dosiert P, Strolin Benedetti M (eds) Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Academic Press, London, pp 137-154
19. Davidson J, Pelton S, Miller RD, Lipper S (1986) Endogenous depression and the response to isocarboxazid. In: Bunney WE, Costa E, Potkin SG (eds) Proceedings of the 15th Collegium Internationale Neuropsychopharmacologium, Vienna 1986. Raven Press, New York, pp 563-565
20. Degen PH, Dieterle W, Schneider W, Czendlik C (1989) Pharmacokinetic interaction of H2-receptor antagonists on brofaromine-HCl. In: Stefanis CN, Soldâtes CR, Rabavilas AD (eds) Psychiatry today. 7th World Congress of Psychiatry, Athens. Excerpta Medica (Intern Congress Series 899, Abstract 405)
21. Degen PH, Cardot M, Czendlik C, Dieterle W (1993) Influence of food on the disposition of the monoamine oxidase A inhibitor brofaromine in healthy volunteers. Biopharm Drug Dispos 14: 209-215
22. Delcker A, Gaertner HJ (1991) Tolerability and antidepressive effect of brofaromine, a short acting reversible MAO-inhibitor - an open study. Eur Neuropsychopharmacol 1: 177-180
23. Delini-Stula A, Humm C (1986) Effects of imipramine and brofaromine, a selective and reversible MAO-A inhibitor, on novelty-oriented behavior in rats. Pharmacopsychiatry 19: 245-246
24. Delini-Stula A, Radeke E, Waldmeier PC (1988) Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. In: Casey DE, Christensen AV (eds) Psychopharmacology: current trends. Springer, Berlin Heidelberg New York Tokyo, pp 147-158
25. Den Boer JM, van Vliet IM, Westenberg HGM (1992) A double-blind comparative study of fluvoxamine and brofaromine in panic disorder. Clin Neuropharmacol 15 [Suppl 1, Pt B]: 91B
26. Fahlen T, Humble M, Koczak C, Nilsson HL (1992) Social phobia and its treatment with brofaromine. Efficacy regarding social phobia symptoms and personality traits. Psychopharmacology 107: B134
27. Feifei N, Kucher K, Fuchs L, Jedrychowski M, Schmidt E, Antonin KH, Bieck PR, Gleiter CH (1993) Role of cytochrome P4502D6 in the metabolism of brofaromine, a new selective MAO-A inhibitor. Eur J Clin Pharmacol 45: 265-269
28. Finberg JP, Youdim MBH (1988) Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase. J Neural Transm 71 [Suppl 26]: 11-16
29. Fritze J, Becker T, Ziegler V, Laux G, Bieck P, Sofie E, Riederer P (1990) Brofaromine (CGP 11 305 A): estimation of plasma concentration by a biological technique as compared to liquid chromatography. J Neural Transm 23 [Suppl]: 197-201
30. Garcia-Borreguerro D, Bronisch T (1992) Improvement of social phobic symptoms after treatment with brofaromine, a reversible and selective inhibitor of MAO-A. Eur Psychiat 7: 93-94
31. Garcia-Borreguerro D, Lauer CJ, Özdaglar A, Wiedmann K, Holsboer F, Krieg J (1992) Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A. Pharmacopsychiatry 25: 261-264
32. Gleiter CH, Mühlbauer B, Gradin-Frimmer G, Antonin KH, Bieck PR (1992a) Administration of sympathomimetic drugs with the selective MAO-A inhibitor brofaromine. Effect on blood pressure. Drug Invest 4: 149-154
33. Gleiter CH, Nilsson E, Mühlbauer B, Antonin KH, Bieck PR (1992b) Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity. J Neural Transm [GenSect] 89: 129-133
34. Gleiter CH, Mühlbauer B, Schulz RM, Nilsson E, Antonin KH, Bieck PR (1994) Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers. J Neural Transm [GenSect] 95: 241-245
35. Greenawalt JW (1972) Localization of monamine oxidase in rat liver mitochondria. Adv Biochem Psychopharmacol 5: 207-226
36. Greenblatt M, Grosser GM, Wechsler H (1964) Differential response of hospitalized depressed patients to somatic therapy. Am J Psychiatry 120: 935-943
37. Hoencamp E, Haffmans PMJ, Knetering H (1991) Brofaromine in therapy resistant depression. Biol Psychiatry 29 (US): 374S
38. Hohagen F, Mayer G, Menche A, Riemann D, Volk S, Meier-Ewert KH, Berger M (1993) Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine - a pilot study. J Sleep Res 2: 250-256
39. Jansen PAF, Haffmans PMJ (1992) Evaluation of brofaromine in depressed elderly patients. International Congress Symposion Series 127: 27-30
40. Johnston JP (1968) Some observations upon a new monoamine oxidase inhibitor in brain tissue. Biochem Pharmacol 17: 1285-1297
41. Kennedy SH, Goldbloom DS, Ralevski E, Davis C, D'Souza JD, Lofchy J (1993) Is there a role for selective MAO-inhibitor therapy in bulima nervosa? A placebo-controlled trial of brofaromine. J Clin Psychopharmacol 13: 415-422
42. Klein DF, Davis JM (1969) Diagnosis and drug treatment of psychiatric disorders. William and Wilkins, Baltimore
43. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393-408
44. Kucher K, Fuchs L, Antonin KH, Schmidt E, Sulkova S, Valek A, Bieck PR (1992) Pharmacokinetics of the monoamine oxidase inhibitor brofaromine in young healthy volunteers and inpatients with chronic renal failure. Naunyn Schmiedebergs Arch 345 [Suppl]: RIO
45. Larsen JK, Holm P, Hoyer E, Mejhede A, Mikkelsen RL, Olesen A, Schaumburg E (1989) Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial. Acta Psychiatr Scand 79: 530-536
46. Lecrubier Y, Guelfi JD (1990) Efficacy of reversible inhibitor of monoamine oxidase-A in various forms of depression. Acta Psychiatr Scand 360 [Suppl]: 18-23
47. Lejoyeux H, Adès J, Rouillon F (1994) Serotonin syndrome: Incidence, symptoms and treatment. CNS Drugs 2: 132-143
48. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin J, Tricamo E, Markowitz JS, Klein DF (1984) Phenelzine v. imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry 41: 669-677
49. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF (1988) Antidepressant specifity in atypical depression. Arch Gen Psychiatry 45: 129-137
50. Marek GJ, Seiden LS (1988) Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior. Psychopharmacology 96: 153-160
51. McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FR, Klien DF (1993) A double-blind cross-over trial of imipramine and phenelzine for outpatients with treatment refractory depression. Am J Psychiatry 150: 118-123
52. Möller HJ, Wendt G (1989) Brofaromine - a selective, reversible, and short acting MAOA inhibitor. Psychiatr Praxis 16: 32-36
53. Möller HJ, Volz HP (1992) Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year. J Affect Disord 26: 163-172
54. Möller HJ, Volz HP (1993) Brofaromine in elderly major depressed patients - a comparative trial versus imipramine. Eur Neuropsychopharmacol 3: 501-510
55. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Hoffmans J (1988) Treatment strategies in depression. II. MAO inhibitors in depression résistent to cyclic antidepressants. Acta Psychiatr Scand 78: 676-683
56. Nolen WA, Haffmans PMJ, Bouvy PF, Daivenvoorden HJ (1993) Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 28: 189-197
57. Ortmann R, Schaub M, Feiner A, Lauber J, Christen P, Waldmeier PC (1984) Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology 84: 22-27
58. Paykel ES (1971) Classification of depressed patients: a cluster analysis derived grouping. Br J Psychiatry 118: 275-288
59. Paykel ES, White JL (1989) A European study of views on the use of monoamine oxidase inhibitors. Br J Psychiatry 155 [Suppl 6]: 9-17
60. Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR, Harrison WM, Tricamo E, Klien DF, Rabkin JG, Markowitz JS, Wager SG (1988) Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responder. Am J Psychiatriy 145: 306-311
61. Quitkin FM, McGrath PJ, Stewart JW, Harrsion W, Wagner SG, Rabkin JG, Tricamo E, Markowitz J, Klein DF (1989) Phenelzine and imipramine in mood reactive depressives. Arch Gen Psychiatry 46: 787-793
62. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wagner SG, OcepekWelikson K, Nunes E, Rabkin JG, Klein DF (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 47: 935-941
63. Quitkin FM, Harrison W, Stewart JW, NcGrath PJ, Tricamo E, Ocepek-Welikson K, Rabkin JG, Wagner SG, Nunes E, Klein DF (1991) Response to phenelzine and imipramine in placebo nonresponders with atypical depression. Arch Gen Psychiatry 48: 319-323
64. Rabkin JG, Quitkin FM, Patrick G, Harrison W, Tricamo E (1985) Adverse reactions to monoamine oxidase inhibitors, part II. Treatment correlates and clinical management. J Clin Psychopharmacol 5: 2-9
65. Raskin A, Schulterbrandt JG, Reatig N, Crook TH, Odle D (1974) Depression subtypes and response to phenelzine, diazepam and a placebo. Arch Gen Psychiatry 30: 66-75
66. Reimann IW, Gleiter CH, Boden C, Joberrt M, Turri M, Antonin KH, Bieck PR (1991) Human pharmaco-EEG of the reversible and selective MAO-A inhibitor brofaromine - comparsion of different modes of data handlung and statistical evaluation. Eur Neuropsychopharmacol 1: 476
67. Roose SP, Glassman AH, Walsh BT, Woodring S (1986) Tricyclic non-responders: phenomenology and treatment. Am J Psychiatry 143: 345-448
68. Sargant W, Dally R (1962) Treatment of anxiety states by anti-depressants. Br Med J 1:5-9
69. Schatzberg AF, Cole JO, Cohen BM, Altesman RI, Sniffin CM (1983) Survey of depressed patients who failed to respond to treatment. In: Davis JM, Maas JW (eds) Affective disorders. American Psychiatric Press, Washington DC
70. Schiwy W, Heath WR, Delini-Stula A (1989) Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine: results of dose-finding trials in depressed patients. J Neural Transm [Suppl 28]: 33-44
71. Schnaitmann C, Erwin VG, Greenawalt JN (1967) The submitochondrial localization of monoamine oxidase. Cell Biol 32: 719-735
72. Steiger A, Holsboer F, Gerken A, Demisch L, Benkert O (1987) Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short acting inhibitor of MAO-A in major endogenous depression. Pharmacopsychiatry 29: 262-269
73. Steiger A, Bardeleben U von, Guldner J, Lauer C, Rothe B, Holsboer F (1993) The sleep EEG and nocturnal hormonal secretion studies on changes during the course of depression and on effects of CNS-active drugs. Prog Neuropsychopharmacol Biol Psychiatry 17: 125-137
74. Strolin Benedetti M, Dosiert P (1987) Overview of the present state of MAO inhibiors. J Neural Transm 23 [Suppl]: 103-119
75. Suzuki O, Katsumata Y, Masukazu Q (1982) Substrate specifity of type A and B monoamine oxidase. In: Kamijo K, Usdin E, Nagatsu T (eds) Monoamine oxidase: basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 74-86
76. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM (1992) Treatment of imipramine-resistant recurrent depression. IV. A double-blind crossover study for anergic bipolar depression. Am J Psychiatry 149: 195-198
77. van Vliet IM, Westenberg HGM, den Boer JA (1991) The efficacy of a reversible MAO inhibitor, brofaromine, in panic disorder. Biol Psychiatry 29 (US): 266S-267S
78. van Vliet IM, den Boer JA, Westenberg HGM (1992) Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 2: 21-29
79. Volz HP, Faltus F, Magyar I, Möller HJ (1994a) Brofaromine in treatment resistant major depressed patients - a comparative trial versus tranylcypromine. J Affect Disord 30: 209-217
80. Volz HP, Heimann H, Bellaire J, Laux G, Möller HJ (1994b) Brofaromine in nonendogenous major depressed inpatients. Results of a preliminary dose-finding trial versus tranylcypromine. Pharmacopsychiatry 4: 152-158
81. Volz HP, Möller HJ (1995) Brofaromine in major depressed in-patients: a controlled clinical trial versus imipramine. Eur Neuropsychopharmacol (submitted)
82. Waldmeier F, Czendlik C, Faigle JW, Moppert J (1988) Disposition and biotransformation of the MAO-A inhibitor trial drug brofaromine in healthy male volunteers. Xlth European Drug Metabolism Workshop, Konstanz, Germany (Abstract No 2.80)
83. Waldmeier PC, Feiner AE, Maître L (1981) Long-term effects of selective MAO inhibitors on MAO activity and amine metabolism. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors - the state of the art. Wiley, Chichester, pp 87-102
84. Waldmeier PC, Baumann PA (1983) Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO-A, on biogenic amine levels and metabolism in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 324: 20-26
85. Waldmieier PC, Feiner AE, Tipton KF (1983a) The monoamine oxidase inhibiting properties of CGP 11 305A. Eur J Pharmacol 94: 73-83
86. Waldmeier PC, Feldtrauer JJ, Stöcklin K, Paul E (1983a) Reversibility of the interaction of CGP 11305 A with MAO-A in vivo. Eur J Pharmacol 94: 101-108
87. Waldmeier PC, Baumann PA, Delini-Stula A, Beranasconi R, Sigg K, Buech O, Feiner AE (1983c) Characterisation of a new, short acting and specific inhibitor of type A monoamine oxidase. Mod Probl Pharmacopsychiatry 19: 31-52
88. Waldmeier PC (1984) Effects of chronic antidepressant treatment on pre- and postsynaptic dopaminergic mechanisms. A short review of the literature and some complementary experiments. Pol J Pharmacol Pharm 36: 197-212
89. Waldmeier PC, Stöcklin K (1989) The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo. Eur J Pharmacol 169: 197-204
90. Waldmeier PC, Stöcklin K (1990) Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide. Eur J Pharmacol 180:297-304
91. 3H]brofaromine to rat intestinal monoamine oxidase A by orally administered tyramine. Eur J Pharmacol 216: 243-247
92. Waldmeier PC (1993) Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine. Prog Neuropsychopharmacol Biol Psychiatry 17: 183-198
93. Waldmeier PC, Glatt A, Jaekel J, Bittiger H (1993a) Brofaromine: a monoamine oxidaseA and serotonin uptake inhibitor. Clin Neuropharmacol 16 [Suppl 2]: S19-S24
94. Waldmeier PC, Graf T, Germer M, Feldtrauer JJ, Howald H (1993b) Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine. Biol Psychiatry 33: 373-379
95. West ED, Daily LJ (1959) Effects of iproniazid in depressive syndromes. Br Med J 1: 1491-1494
96. Wollmann H, Nilsson E, Antonin KH, Bieck PR (1985) Tryptamine kinetics in human volunteers. In: Boulton AA, Maître L, Bieck PR, Riederer P (eds) Neurobiology of the trace amines. Humana Press, Clifton NJ, pp 361-378
97. Yang HY, Neff NH (1973) Beta-phenylethylamine: a specific substrate of type B monoamine oxidase in brain. J Pharmacol Exp Ther 187: 365-371
98. Zeeh J, Bermann W, Fuchs L, Antonin KH, Platt D, Bieck RP (1993) Pharmacokinetics of brofaromine in young healthy volunteers and frail elderly patients - can quantitative liver function test predict individual kinetic behaviour? XVth World Congress of Gerontology, July 4-7, Budapest
99. Zisook S (1985) A clinical overview of monoamine oxidase inhibitors. Psychosomatics 26: 240-246